

REMARKS

The Applicants petition the Commissioner for a 4-month extension of time : a separate petition accompanies this amendment.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page(s) is/are captioned **"Version with markings to show changes made."**

I. **Election/Restriction**

In the above referenced Office Action, the Examiner divided the claims into the following groups: I. Claims 1-12 and 25-40, drawn to a human cell line that is able to produce one or more cytokines; II. Claims 13-24, drawn to a method of improving the production of interferon-alpha from a human cell line; III. Claims 13 and 19, drawn to a method of improving the production of interferon-beta from a human cell line; IV. Claims 13 and 19, drawn to a method of improving the production of interferon-gamma from a human cell line; V. Claims 13 and 19, drawn to a method of improving the production of granulocyte macrophage stimulating factor from a human cell line; VI. Claims 13 and 19, drawn to a method of improving the production of granulocyte colony stimulating factor from a human cell line; VII. Claims 13 and 19, drawn to a method of improving the production of interleukin-2 factor from a human cell line; VIII. Claims 13 and 19, drawn to a method of improving the production of interleukin-3 factor from a human cell line; IX. Claims 13 and 19, drawn to a method of improving the production of interleukin-7 factor from a human cell line; X. Claims 13 and 19, drawn to a method of improving the production of interleukin-8 factor from a human cell line; XII. Claims 13 and 19, drawn to a method of improving the production of interleukin-10 factor from a human cell line; and XII. Claims 13 and 19, drawn to a method of improving the production of interleukin-12 factor from a human cell line. In addition, the Examiner requested an election of species of a single disclosed species for the priming agent and the inducing agent .

Attorney Docket No. 54099.8003.US01

In response, Applicants elect Group I without traverse. Non-elected claims 13-24 have been canceled. Additionally, Applicants elect species (a) the priming compound phorbol myristate acetate and the inducing agent species (f) poly I:C.


Upon allowance of the generic claims, Applicant(s) request considerations of claims to additional species which are written in dependent form or which otherwise include all the limitations of the allowed generic claims as provided by 37 C.F.R. §1.141.

II. Amendments

By this amendment, claims 13-24 have been cancelled due to the restriction requirement. Claims 9-10, 27-28, and 35-36 have been cancelled due to the election of species. Claims 8, 11, 26, 29, 34, and 37 are amended to remove matter drawn to a non-elected invention. It is Applicants' understanding that remaining pending claims 1-8, 11-12, 25-26, 29-34, and 37-40 read on elected species for the priming compound phorbol myristate acetate and the inducing agent poly I:C.

Date: 08-22-02

Respectfully submitted,
Perkins Coie LLP


Peter J. Dehlinger
Registration No. 28,006

Correspondence Address:
Customer No. 22918
(650) 838-4300

USSN: 09/722,109

Version with markings to show changes made

8. (Twice Amended) The human cell line according to claim 7, wherein priming means exposing said modified cells to phorbol myristate acetate (PMA)[or interferon- β].

11. (Twice Amended) The human cell line according to claim 7, wherein inducing means exposing said cells to at least one non-microbial inducing agent comprising[selected from the group consisting of] poly(I):poly(C)(poly IC)[, or poly r(I):poly r(C)(poly rIC), heparin, dextran sulfate, cycloheximide, Actinomycin D, sodium butyrate, a calcium ionophore and chondroitin sulfate].

26. (Amended) The human cell line according to claim 25, wherein priming means exposing said modified cells to phorbol myristate acetate (PMA)[or interferon- β].

29. (Amended) The human cell line according to claim 25, wherein inducing means exposing said cells to at least one non-microbial inducing agent comprising[selected from the group consisting of] poly(I):poly(C)(poly IC)[, or poly r(I):poly r(C)(poly rIC), heparin, dextran sulfate, cycloheximide, Actinomycin D, sodium butyrate, a calcium ionophore and chondroitin sulfate].

34. (Amended) The human cell line according to claim 33, wherein priming means exposing said modified cells to phorbol myristate acetate (PMA)[or interferon- β].

37. (Amended) The human cell line according to claim 33, wherein inducing means exposing said cells to at least one non-microbial inducing agent comprising[selected from the group consisting of] poly(I):poly(C)(poly IC)[, or poly r(I):poly r(C)(poly rIC), heparin, dextran sulfate, cycloheximide, Actinomycin D, sodium butyrate, a calcium ionophore and chondroitin sulfate].